Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 6:42 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1081–1104 of 3,925 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: HTN Clear all

Conditions: Hypertension
Interventions: Darusentan, Guanfacine; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 35 Years to 80 Years
Enrollment: 661 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 85
States / cities: Birmingham, Alabama • Huntsville, Alabama • Montgomery, Alabama + 69 more

Conditions: Cardiovascular Disease (CVD), Heart Failure, Aortic Stenosis, Aortic Stenosis Disease, Hypertension, Hypertension (HTN), Hypertrophic Cardiomyopathy Patients, Hypertrophic Cardiomyopathy Without Obstruction, Hypertrophic Cardiomyopathy, Obstructive, Dilated Cardiomyopathy (DCM), Dilated Cardiomyopathy, Dilated Cardiomyopathy, Familial
Interventions: Not listed
Lead sponsor: Prolaio; Industry
Eligibility: 18 Years and older
Enrollment: 5,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Chronic Kidney Disease, Blood Pressure, Anemia
Interventions: Darbepoetin; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Hypertension
Interventions: Minocycline; Drug
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 85 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Glaucoma, Ocular Hypertension
Interventions: Kinezodianone R hydrochloride, Placebo; Drug
Lead sponsor: Laboratoires Thea; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Glendale, California

Conditions: Pulmonary Arterial Hypertension
Interventions: Macitentan; Drug
Lead sponsor: Actelion; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 8
States / cities: Boston, Massachusetts • Minneapolis, Minnesota • St Louis, Missouri + 5 more

Conditions: Persistent Pulmonary Hypertension of the Newborn
Interventions: Not listed
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: Up to 12 Months
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2028
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Intrahepatic Cholangiocarcinoma (Icc)
Interventions: EXOMIC small RNA sequencing, EXOMIC assay (qRT-PCR validation); Diagnostic Test
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 230 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Duarte, California

Conditions: Hypertension
Interventions: Lifestyle counseling; Behavioral
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 19 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 2
States / cities: Milwaukee, Wisconsin

Conditions: Hypertension (HTN)
Interventions: Combination Product: FDC of spironolactone and ER torsemide, Combination Product: Stabilized doses of loop diuretic and finerenone; Drug
Lead sponsor: Sarfez Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Vienna, Virginia

Conditions: Heart Failure
Interventions: aliskiren; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years and older
Enrollment: 280 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Pulmonary Hypertension
Interventions: Pulmonary artery pressure measurements; Other
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Hypertension, Food Insecurity, Diet, Mediterranean
Interventions: Food Subsidy, 6 months, Food Subsidy, 12 months, Lifestyle Support, 6 months, Lifestyle Support, 12 months, Food Delivery, 6 months, Food Delivery, 12 months; Other · Behavioral
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 99 Years
Enrollment: 525 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 2
States / cities: Chapel Hill, North Carolina • Durham, North Carolina

Conditions: Essential Hypertension
Interventions: Azilsartan medoxomil and chlorthalidone, Olmesartan medoxomil and hydrochlorothiazide; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 1,071 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 84
States / cities: Gulf Shores, Alabama • Litchfield Park, Arizona • Mesa, Arizona + 81 more

Conditions: Pulmonary Arterial Hypertension
Interventions: CXA-10; Drug
Lead sponsor: Gladwin, Mark, MD; Individual
Eligibility: 18 Years to 80 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Obesity, Hypertension
Interventions: L-NMMA, Trimethaphan; Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 30 Years to 50 Years · Female only
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2016
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Pulmonary Hypertension, Infant, Premature
Interventions: Not listed
Lead sponsor: Mount Sinai Hospital, Canada; Other
Eligibility: 14 Days and older
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Obesity
Interventions: Blocked, Intact; Drug
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years to 60 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2015
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Blood Pressure, Hypertension, Pregnancy Related, Health Equity
Interventions: PDSA Cycles; Other
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 47 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Hypertension
Interventions: Not listed
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 21 Years to 65 Years
Enrollment: 670 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2024
U.S. locations: 2
States / cities: Bethesda, Maryland • Jackson, Mississippi

Conditions: Hypertension, Insulin Resistance, Metabolic Syndrome
Interventions: Olmesartan medoxomil, Losartan potassium, Atenolol; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 10
States / cities: Birmingham, Alabama • San Diego, California • Miami, Florida + 7 more

Conditions: Hypertension, Physical Activity, Diet, Medication Adherence
Interventions: Therapeutic Lifestyle Changes (MINT-TLC), Usual Care; Behavioral
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Enrollment: 194 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 4
States / cities: Brooklyn, New York • New York, New York

Conditions: Infection, Heart Failure, Chronic Obstructive Pulmonary Disease, Asthma, Gout Flare, Chronic Kidney Diseases, Hypertensive Urgency, Atrial Fibrillation Rapid, Anticoagulants; Increased
Interventions: Not listed
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Osteoporosis, Osteopenia
Interventions: melatonin, sugar pill; Dietary Supplement
Lead sponsor: Duquesne University; Other
Eligibility: 45 Years to 54 Years · Female only
Enrollment: 19 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Search by objective public record fields.

DORADO-AC-EX - A Long-Term Safety Extension Study to the Phase 3 DORADOC-AC Study (Protocol DAR-312) of Darusentan in Resistant Hypertension

Study of the Progression of Chronic Cardiovascular Conditions

Mechanisms of EPO-induced Hypertension

Study 3: Minocycline Decreases Microglia Activation

Safety Assessment of T4090 Eye Drops in Ocular Hypertensive or Glaucomatous Patients.

REPAIR: Right vEntricular Remodeling in Pulmonary ArterIal hypeRtension

PTGS1 Genetic Variation and Increased Risk for Persistent Pulmonary Hypertension of the Newborn

Liquid Biopsy Using Exosomal miRNA Enables Risk Stratification of Potential Metastasis in Patients With Intrahepatic Cholangiocarcinoma.

Improving Hypertension Control

A Study Comparing the Clinical Benefit of Finerenone Versus a Fixed Dose Combination (FDC) of Extended-Release Torsemide and Spironolactone in Patients With Hypertension and Chronic Kidney Disease

"ALOFT - Aliskiren Observation of Heart Failure Treatment": Efficacy and Safety of Aliskiren Added on Top of Standard Therapy in Adults (≥ 18 Years) With Stable Heart Failure

Contrast Enhanced PA Pressure Measurements

Healthy Food First

Efficacy and Safety of Azilsartan Medoxomil and Chlorthalidone Compared to Olmesartan Medoxomil and Hydrochlorothiazide in Participants With Moderate to Severe Hypertension.

Oral CXA-10 in Pulmonary Arterial Hypertension

Pathophysiology of Cardiometabolic Risk Factors in African Americans

Novel Echocardiographic Methods for Early Identification of Neonates at Risk for Chronic Pulmonary Hypertension

The Autonomic Nervous System and the Metabolic Syndrome

Community-based Implementation of Adapted STAC

Genomics, Environmental Factors and Social Determinants of Cardiovascular Disease in African-Americans Study (GENE-FORECAST)

A Comparison of the Effect of Olmesartan Medoxomil, Losartan Potassium, and Atenolol on the Ability of Overweight Patients With High Blood Pressure to Respond to Insulin

Practice-based Trial of Blood Pressure Control in African Americans

Prediction of Expected Length of Hospital Stay Using Machine Learning

Melatonin Osteoporosis Prevention Study